Cover Image
市場調查報告書

夜間頻尿 : 開發平台分析

Nocturia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213118
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
夜間頻尿 : 開發平台分析 Nocturia - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 29 Pages
簡介

夜間頻尿,定義為夜間必須最少2次起床排尿的症狀。男女皆由於年齡增加,以及各種理由,產生這種症狀。夜間頻尿的主要原因,為充血性心臟衰竭和下肢水腫,睡眠障礙(閉塞型睡眠呼吸中止症等),部分醫藥品(利尿劑、強心苷類、鋰、加氧甲乙醚、苯妥英、Propoxyphene、維他命D攝取過量等),睡前過量攝取水分(特別是咖啡和咖啡因飲料、酒精等)等。主要的治療方法有抗膽鹼劑療法等。

本報告提供全球各國的夜間頻尿治療用的開發中產品的開發情形相關分析、產品開發與上市的最新趨勢,及各臨床實驗階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

夜間頻尿概要

治療藥的開發

  • 夜間頻尿的開發中產品:概要
  • 夜間頻尿的開發中產品:比較分析

各企業開發中的夜間頻尿治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

夜間頻尿治療藥:開發中的產品一覽(各企業)

夜間頻尿開發治療藥的企業

  • Allergan, Inc.
  • Ferring International Center S.A.
  • 大日本住友製藥
  • Vantia Therapeutics

夜間頻尿:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • afacifenacin
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ASP-7035
  • 醋酸去氨加壓素
  • FE-999309
  • fedovapagon
  • Paxerol

夜間頻尿治療藥:開發中產品的最新趨勢

夜間頻尿治療藥:開發暫停的產品

夜間頻尿相關產品的開發的里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9535IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nocturia - Pipeline Review, H2 2017, provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape.

Nocturia is defined as need to urinate at least twice during the night. This condition becomes more common as people age and occurs in both men and women, sometimes for different reasons. Causes of nocturia include congestive heart failure, edema of lower extremities, sleeping disorders such as obstructive sleep apnea, certain drugs, including diuretics (water pills), cardiac glycosides, demeclocycline, lithium, methoxyflurane, phenytoin, propoxyphene, and excessive vitamin d and drinking too much fluid before bedtime, especially coffee, caffeinated beverages, or alcohol. Treatment includes anticholinergic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nocturia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nocturia (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 3 and 2 respectively.

Nocturia (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nocturia (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nocturia (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nocturia (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nocturia (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nocturia - Overview
    • Nocturia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Nocturia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nocturia - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • Ferring International Center SA
    • Sanwa Kagaku Kenkyusho Co Ltd
    • Vantia Therapeutics
  • Nocturia - Drug Profiles
    • (acetaminophen + ibuprofen) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-7035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-7398 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • desmopressin acetate ODT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FE-201836 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fedovapagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SK-1404 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nocturia - Dormant Projects
  • Nocturia - Product Development Milestones
    • Featured News & Press Releases
      • Feb 13, 2017: Scottish Medicines Consortium Rejects Noqdirna For Use Within NHS Scotland
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Nocturia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Nocturia - Pipeline by Astellas Pharma Inc, H2 2017
  • Nocturia - Pipeline by Ferring International Center SA, H2 2017
  • Nocturia - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2017
  • Nocturia - Pipeline by Vantia Therapeutics, H2 2017
  • Nocturia - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Nocturia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top